Cargando…

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease

BACKGROUND & AIMS: Approximately one‐third of patients with non‐alcoholic fatty liver disease (NAFLD) show signs of mild‐to‐moderate iron overload. The impact of histological iron deposition on the clinical course of patients with NAFLD has not been established. METHODS & RESULTS: For this r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eder, Sebastian K., Feldman, Alexandra, Strebinger, Georg, Kemnitz, Jana, Zandanell, Stephan, Niederseer, David, Strasser, Michael, Haufe, Heike, Sotlar, Karl, Stickel, Felix, Paulweber, Bernhard, Datz, Christian, Aigner, Elmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Metabolic & Toxic Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496452/ https://www.ncbi.nlm.nih.gov/pubmed/32378295 http://dx.doi.org/10.1111/liv.14503

Ejemplares similares

PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center
por: Semmler, Georg, et al.
Publicado: (2021)

Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients
por: Denkmayr, Lukas, et al.
Publicado: (2018)

Low rate of new‐onset primary biliary cholangitis in a cohort of anti‐mitochondrial antibody‐positive subjects over six years of follow‐up
por: Zandanell, S., et al.
Publicado: (2019)

NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction
por: Verwer, Bart J., et al.
Publicado: (2020)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma
por: Nardo, Alexander D., et al.
Publicado: (2020)

Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease
por: Sangineto, Moris, et al.
Publicado: (2020)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Absence of Bsep/Abcb11 attenuates MCD diet‐induced hepatic steatosis but aggravates inflammation in mice
por: Fuchs, Claudia D., et al.
Publicado: (2020)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population
por: Damba, Turtushikh, et al.
Publicado: (2020)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation
por: Kim, Dae Hyun, et al.
Publicado: (2020)

Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review
por: Draijer, Laura G., et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
por: Colosimo, Santo, et al.
Publicado: (2021)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008‐2019
por: Sugiyama, Aya, et al.
Publicado: (2021)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022)

Inhibition of polyploidization in Pten‐deficient livers reduces steatosis
por: Moreno, Eva, et al.
Publicado: (2022)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism
por: Stechemesser, Lars, et al.
Publicado: (2016)

NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
por: Niederseer, David, et al.
Publicado: (2021)

Genetic Variants Determine Treatment Response in Autoimmune Hepatitis
por: Zandanell, Stephan, et al.
Publicado: (2023)

Changing Metabolic Patterns along the Colorectal Adenoma–Carcinoma Sequence
por: Tevini, Julia, et al.
Publicado: (2022)

Obesity as an Emerging Risk Factor for Iron Deficiency
por: Aigner, Elmar, et al.
Publicado: (2014)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
por: van den Berg, Eline H., et al.
Publicado: (2019)

Cardiovascular Risk Assessment by SCORE2 Predicts Risk for Colorectal Neoplasia and Tumor-Related Mortality
por: Wernly, Sarah, et al.
Publicado: (2022)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tv98lt8m698udptmipq000qndk